Clinical Trials | December 09, 2024
Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr
Aims to become India’s leading cancer testing company
Aims to become India’s leading cancer testing company
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Subscribe To Our Newsletter & Stay Updated
